AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability
AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline...
Finanical Reports
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...
Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels
Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...
Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued...
Abbott Reports Mixed 2023 Results with Q4 Growth Offsetting Full-Year Decline
US healthcare company Abbott (NYSE: ABT) has released its financial results for the fourth quarter...
J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth
Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for...
Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...
Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast
Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion...